The main objective of the study was to determine whether EVs released by tumor cells genetically engineered for overexpression of proinflammatory IL-12 and/or shRNA targeting suppressor TGF-β1 may lose protumor activity and acquire antitumor potential. This evidence concerns the gene TGFB1 and neoplasm.